Mirion Technologies, Inc. (NYSE: MIR)

Mirion Technologies, Inc., referred to as MIR, is a global provider of radiation detection, measurement, analysis, and monitoring products and services for the medical and industrial end markets (Mirion Technologies, Inc., n.d.). The company has a rich history dating back over 60 years and has established a reputation for providing high-quality products and services to its customers.

Mirion's main business activities revolve around providing solutions for the medical, nuclear energy, defense, laboratories, and scientific research markets. The company's products and services are designed to help its customers safely leverage the power of ionizing radiation for applications that benefit humanity. Mirion operates through two reportable business segments: Medical and Technologies. The Medical segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation, while the Technologies segment is focused on addressing critical radiation safety, measurement, and analysis applications across nuclear energy, defense, laboratories, and other industrial markets.

The Medical segment is comprised of several product categories, including cancer diagnostics and therapeutics quality and safety, nuclear medicine and medical imaging, and dosimetry services. The company's products in this segment are designed to help ensure that oncologists' prescriptions and intended doses are accurately, consistently, and safely delivered to patients. The Technologies segment is also comprised of several product categories, including radiation detection and measurement, nuclear energy, defense, laboratories, and scientific research. The company's products in this segment are designed to help its customers safely and efficiently manage radiation in various applications, including nuclear power generation, waste management, and defense.

Mirion's position within the industry is strong, with a reputation for providing high-quality products and services to its customers. The company's key competitors include other companies that provide radiation detection and measurement products and services, such as Nuctech Company Limited and Landauer, Inc. Mirion's competitive strengths include its trusted ionizing radiation detection and measurement provider, broad and complementary product and service portfolio, large installed base driving recurring revenue, technical complexity creating high barriers to entry, and global footprint designed to meet local customer needs. The company's strategy is focused on exploiting under-penetrated market opportunities, expanding its addressable market, developing new products and services, continuously improving its cost structure and productivity, pursuing strategic acquisitions and other transactions, and continuously monitoring potential acquisitions.

Mirion sells its products and services through its direct sales organization and indirectly through its global network of independent, third-party sales representatives and distributors. The company has 50 sales offices throughout North America, Europe, and Asia, and as of December 31, 2023, its sales and marketing personnel consisted of 273 employees, which represents approximately 9% of its total workforce.

In terms of research and development, Mirion invests in both technology research and product development to fulfill its strategic objectives. The company engages in research and development activities at most of its facilities worldwide and has a team of approximately 150 software engineers, 292 scientists, technicians, and other engineers, representing approximately 15% of its total workforce.

Mirion is committed to creating positive change through sustainable and responsible operations. The company has published its inaugural Corporate Social Responsibility Report and has committed to robust oversight of ESG issues. Mirion's Board of Directors has direct oversight of ESG, including environmental, climate risk, and sustainability matters, as well as employee health and safety.